Private equity investor Nordic Capital on Wednesday offered to buy Advanz Pharma, valuing the drugmaker at $846 million as part of a move to invest in accelerating the company’s pipeline of innovative specialty pharmaceutical products.
Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share and can also elect a non-cash alternative offer to receive unlisted shares in Cidron Aida for each Advanz Pharma share.
Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services.
Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested more than EUR 15.5 billion in over 110 investments. The most recent fund is Nordic Capital Fund X with EUR 6.1 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, Denmark, Finland, Norway, Germany, the UK and the US.
Source: Reuters
Image Source
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.